Skip to content
Politically.com Search all
Menu

Final rule 2026-07860

Medical Devices; Immunology and Microbiology Devices; Classification of the Alzheimer's Disease Pathology Assessment Test

The Food and Drug Administration (FDA, the Agency, or we) is classifying the Alzheimer's disease pathology assessment test into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the Alzheimer's disease pathology assessment test. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Source: FederalRegister.gov API v1Recently refreshed. Last successful refresh: 2026-07-31 22:49:02 UTC.

Source-supplied record

Document details

Document number
2026-07860
Published
Apr 22, 2026
Effective
Apr 22, 2026
Comments close
Not supplied
Federal Register citation
91 FR 21379

Docket identifiers

  • Docket No. FDA-2026-N-3930

CFR references

  • Title 21, part 866